Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
January 28, 2009

Omeros Achieves $3.1M Milestone under a Schizophrenia Partnership with The Stanley Medical Research Institute

  • Omeros was awarded $3.1 million in a second tranche of equity and grant funding from The Stanley Medical Research Institute (SMRI) to support late-stage preclinical development of its schizophrenia drug candidates. The funds serve as a milestone payment to Omeros for having successfully met preclinical compound optimization criteria.

    Omeros' schizophrenia product candidates inhibit the phosphodiesterase 10 (PDE10) enzyme. “We believe that our program could provide product candidates that have benefits not offered by existing antipsychotics and we are working to advance into clinical trials next year,” says Gregory A. Demopulos, M.D., chairman and CEO.

    In December 2006, Omeros entered into an agreement with SMRI to develop its PDE10 inhibitors through Phase I trials. The $2.6 million first tranche of grant and equity funding was received at signing of the deal, and Omeros stands to earn another $3.3 million.

    ---

     

Related content

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.